04.29.24 -- Companies To Watch: OSE Immunotherapeutics

Pharma and biotech companies prioritize innovation in areas of high and rare unmet need. Though the R&D landscape for these rare diseases can be difficult to navigate, changes are on the horizon.

The biopharmaceutical industry is increasingly employing micro-flow imaging for particle characterization, owing to the superior insights it can afford into product quality and process controls.

Participant travel is an area consistently cited as a leading barrier to participation. Explore examples of unique challenges encountered by participants and how Greenphire worked to eliminate them.

An increasing number of poorly soluble APIs are the cornerstone of cutting-edge therapies, necessitating equally complex formulation technologies to maintain or improve solubility and, ultimately, bioavailability.

bsAbs are revolutionizing medicine by targeting two disease mechanisms simultaneously. Learn how an innovative platform offers excellent pairing and significantly enhances productivity and quality.

Get pragmatic details of what it took to build a successful partnership, why it has become a model for other departments within Regeneron, and lessons learned you can apply in your organization.

Orphan drugs are extremely complex and hard to create. To help address this market barrier, learn more about controlling the process, identifying a global supply chain, and being flexible to scale with projects.

Review the advantages and limitations of transcriptional assays versus reporter gene assays and how the transcriptional assay compares to ddPCR and flow cytometry for analysis of CGTs.